$XORTX Therapeutics Inc.(XRTX)$ Xortx Therapeutics is a pharmaceutical company, and one of its primary clinical programs focuses on autosomal dominant polycystic kidney disease (ADPKD). That’s a rare disease that, according to the company, affects over 10 million individuals worldwide.
The study, XRX-OXY-101, evaluated XORLO’s effectiveness in treating ADPKD. The trial involved 88 patients and found that XORLO was “well tolerated across the various dosing regimens.” There were no identified safety issues.
The most notable result, however, was a “substantial increase in the bioavailability” of XORLO. This doesn’t necessarily mean the drug will be effective in treating ADPKD. However, it does suggest that oxypurinol can be efficiently introduced into and absorbed by the body, under the right circumstances.
The market’s response to the clinical trial results concerning XORLO was immediate. XRTX stock shot up 50% early in today’s trading session. However, shares lost ground and were soon up by “only” 30%.
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
关注我们